468 related articles for article (PubMed ID: 26851562)
21. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
22. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
Kimmey MB
Am J Med; 2004 Sep; 117 Suppl 5A():72S-78S. PubMed ID: 15478856
[TBL] [Abstract][Full Text] [Related]
23. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
[TBL] [Abstract][Full Text] [Related]
24. Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Raju N; Sobieraj-Teague M; Hirsh J; O'Donnell M; Eikelboom J
Am J Med; 2011 Jul; 124(7):621-9. PubMed ID: 21592450
[TBL] [Abstract][Full Text] [Related]
25. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Guirguis-Blake JM; Evans CV; Perdue LA; Bean SI; Senger CA
JAMA; 2022 Apr; 327(16):1585-1597. PubMed ID: 35471507
[TBL] [Abstract][Full Text] [Related]
26. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.
García Rodríguez LA; Martín-Pérez M; Hennekens CH; Rothwell PM; Lanas A
PLoS One; 2016; 11(8):e0160046. PubMed ID: 27490468
[TBL] [Abstract][Full Text] [Related]
27. Aspirin and Cancer.
Patrignani P; Patrono C
J Am Coll Cardiol; 2016 Aug; 68(9):967-76. PubMed ID: 27561771
[TBL] [Abstract][Full Text] [Related]
28. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
Guirguis-Blake JM; Evans CV; Senger CA; O'Connor EA; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):804-13. PubMed ID: 27064410
[TBL] [Abstract][Full Text] [Related]
29. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
; Davidson KW; Barry MJ; Mangione CM; Cabana M; Chelmow D; Coker TR; Davis EM; Donahue KE; Jaén CR; Krist AH; Kubik M; Li L; Ogedegbe G; Pbert L; Ruiz JM; Stevermer J; Tseng CW; Wong JB
JAMA; 2022 Apr; 327(16):1577-1584. PubMed ID: 35471505
[TBL] [Abstract][Full Text] [Related]
30. A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Wu IC; Hsieh HM; Yu FJ; Wu MC; Wu TS; Wu MT
Eur J Clin Invest; 2016 Feb; 46(2):130-40. PubMed ID: 26640116
[TBL] [Abstract][Full Text] [Related]
31. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Butalia S; Leung AA; Ghali WA; Rabi DM
Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
[TBL] [Abstract][Full Text] [Related]
32. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
[TBL] [Abstract][Full Text] [Related]
33. Aspirin for the primary prevention of adverse cardiovascular events.
Estes K; Thomure J
Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
[TBL] [Abstract][Full Text] [Related]
34. A review and study of aspirin utilization for the primary prevention of cardiovascular events in a psychiatric population.
Victor K; Skelly M; Mulcahy K; Demler TL; Trigoboff E
Int Clin Psychopharmacol; 2018 Sep; 33(5):274-281. PubMed ID: 29939889
[TBL] [Abstract][Full Text] [Related]
35. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
[TBL] [Abstract][Full Text] [Related]
36. [Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention].
Volpe M; Abrignani MG; Borghi C; Coccheri S; Gresele P; Patti G; Trimarco B; De Caterina R
G Ital Cardiol (Rome); 2014; 15(7-8):442-51. PubMed ID: 25174598
[TBL] [Abstract][Full Text] [Related]
37. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin.
Hirata Y; Kataoka H; Shimura T; Mizushima T; Mizoshita T; Tanida S; Kamiya T; Joh T
Scand J Gastroenterol; 2011 Jul; 46(7-8):803-9. PubMed ID: 21501103
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies.
Calderone D; Greco A; Ingala S; Agnello F; Franchina G; Scalia L; Buccheri S; Capodanno D
Thromb Haemost; 2022 Mar; 122(3):445-455. PubMed ID: 34638150
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
